Dimethindene

Dimethindene

SCHEMBL359490

CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1.O=C(O)/C=C\C(=O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of Dimethindene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 8/20 0.82
CHRM1 P11229 20/20 0.82
CHRM2 P08172 19/20 0.82
CHRM4 P08173 19/20 0.82
CHRM5 P08912 19/20 0.82
CHRM3 P20309 19/20 0.82
CYP2D6 P10635 3/20 0.82
KCNH2 Q12809 3/20 0.82
CYP1A2 P05177 1/20 0.82
CYP2C9 P11712 1/20 0.82
TSHR P16473 1/20 0.82
CYP2C19 P33261 1/20 0.82
HTR1A P08908 1/20 0.82
ADRA2A P08913 1/20 0.82
DRD1 P21728 1/20 0.82
PTGS1 P23219 1/20 0.82
SLC6A2 P23975 1/20 0.82
SLC6A4 P31645 1/20 0.82
ADRA1A P35348 1/20 0.82
OPRM1 P35372 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethindene SCHEMBL29887834 1.00 CHRM1 (0.82) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL1972832 1.00 CHRM1 (0.82) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL29455130 1.00 CHRM1 (0.82) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL19284560 0.90 CHRM1 (1.00) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL30436315 0.90 CHRM1 (1.00) CHRM1CHRM2CHRM4CHRM5CHRM3
(S)-(+)-Dimethindene SCHEMBL30910954 0.90 CHRM1 (1.00) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL29676184 0.90 CHRM1 (1.00) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL18759 0.90 CHRM1 (1.00) CHRM1CHRM2CHRM4CHRM5CHRM3
Dimethindene SCHEMBL28142887 0.81 CHRM1 (0.76) CHRM1CHRM2CHRM4CHRM5CHRM3
SCHEMBL6276908 0.78 HRH1 (1.00) CHRM1CHRM2CHRM4CHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 977 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026525-A1 HETEROCYCLIC COMPOUNDS AS PHYSIOLOGICAL COOLANTS SYMRISE AG (DE) 2025-02-06 WO claimed
EP-4469439-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-12-04 EP claimed
EP-3689324-B1 NEW COOLING AGENTS AND PREPARATIONS COMPRISING THEM SYMRISE AG (DE) 2024-11-20 EP claimed
US-20240000746-A1 New Cooling Agents and Preparations Containing Them SYMRISE AG (DE) 2024-01-04 US claimed
EP-4247791-A2 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2023-09-27 EP claimed
WO-2023143741-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-08-03 WO claimed
WO-2023144326-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-08-03 WO claimed
WO-2022105986-A1 NOVEL COOLING AGENTS AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2022-05-27 WO claimed
WO-2022106452-A2 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2022-05-27 WO claimed
EP-3689324-A1 NEW COOLING AGENTS AND PREPARATIONS COMPRISING THEM Symrise AG (DE) 2020-08-05 EP claimed
US-20050074414-A1 Penetrating pharmaceutical foam FOAMIX LTD. (IL) 2005-04-07 US claimed
US-20050069566-A1 Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions FOAMIX LTD. (IL) 2005-03-31 US claimed
WO-2005018530-A2 PENETRATING PHARMACEUTICAL FOAM FOAMIX LTD. (US) 2005-03-03 WO claimed
WO-2005011567-A2 FOAM CARRIER CONTAINING AMPHIPHILIC COPOLYMERIC GELLING AGENT FOAMIX LTD. (US) 2005-02-10 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
EP-0783885-A2 Use of taxol for the manufacture of a medicament for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 1997-07-16 EP claimed
EP-0783886-A2 Use of taxol for the manufacture of a medicament for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 1997-07-16 EP claimed
EP-0584001-B1 Use of taxol for the manufacture of a medicament for the treatment of cancer BRISTOL MYERS SQUIBB CO (US) 1997-05-14 EP claimed
EP-0584001-A1 Products containing taxol for use in cancer therapy BRISTOL-MYERS SQUIBB COMPANY (US) 1994-02-23 EP claimed
US-4256743-A PHENOTHIAZINES, ETHYLENEDIAMINES, INDENES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1981-03-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240000746-A1 New Cooling Agents and Preparations Containing Them TTPA, TREH, TAS2R45 HRH1 3757/4885CHRM1 3278/4885CHRM2 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.